Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Calcipotriene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 13/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.67 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | GC | P02774 | 1/20 | 0.64 |
| ▸ | RXRA | P19793 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calcipotriene SCHEMBL13287283 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL21849105 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL5001249 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL24066882 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL2455291 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL23339038 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL22364326 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL22364325 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL22364327 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR | |
| Calcipotriene SCHEMBL2470594 | 1.00 | VDR (1.00) | VDRADORA3SLC6A2NR1I2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165061-B1 | USE OF COMPOUND PREPARATION MADE OF VITAMIN D METABOLITES OR VITAMIN D ANALOGUES AND PARTIAL ESTROGEN AGONISTS FOR TREATING OSTEOPOROSIS | SCHERING AG (DE) | 2005-10-19 | — | — | EP | claimed |
| US-20030166622-A1 | Vitamin D derivatives with acyloxy groups in the side chains, process for their production, and the use for the production of pharmaceutical agents | SCHERING AG (DE) | 2003-09-04 | — | — | US | claimed |
| WO-2003042171-A1 | VITAMIN D DERIVATIVES WITH ACYLOXY GROUPS AT THE 24-POSITION OF THE SIDE CHAIN, A METHOD FOR PRODUCING THE SAME AND USE THEREOF IN PRODUCTION OF MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-22 | — | — | WO | claimed |
| JP-2002541188-A | — | — | 2002-12-03 | — | — | JP | claimed |
| EP-1165061-A2 | COMPOUND PREPARATION MADE OF VITAMIN D METABOLITES OR VITAMIN D ANALOGUES AND AN OESTROGENIC COMPONENT FOR TREATING OSTEOPOROSIS | Schering Aktiengesellschaft (DE) | 2002-01-02 | — | — | EP | claimed |
| WO-2000061123-A2 | COMPOUND PREPARATION MADE OF VITAMIN D METABOLITES OR VITAMIN D ANALOGUES AND AN OESTROGENIC COMPONENT FOR TREATING OSTEOPOROSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-10-19 | — | — | WO | claimed |
| US-20200129445-A1 | LIPID NANOPARTICLE FORMULATION | ARES CAPITAL CORPORATION, AS AGENT | 2020-04-30 | — | — | US | disclosed |
| US-7700580-B2 | Process for preparation of pharmaceutically pure anhydrous calcipotriol | INSTYTUT FARMACEUTYCZNY (PL) | 2010-04-20 | — | — | US | disclosed |
| US-20080214876-A1 | Process for Preparation of Pharmaceutically Pure Anhydrous Calcipotriol | INSTYTUT FARMACEUTYCZNY (PL) | 2008-09-04 | — | — | US | disclosed |
| EP-1165061-B1 | USE OF COMPOUND PREPARATION MADE OF VITAMIN D METABOLITES OR VITAMIN D ANALOGUES AND PARTIAL ESTROGEN AGONISTS FOR TREATING OSTEOPOROSIS | SCHERING AG (DE) | 2005-10-19 | — | — | EP | disclosed |
| US-20030166622-A1 | Vitamin D derivatives with acyloxy groups in the side chains, process for their production, and the use for the production of pharmaceutical agents | SCHERING AG (DE) | 2003-09-04 | — | — | US | disclosed |
| WO-2003042171-A1 | VITAMIN D DERIVATIVES WITH ACYLOXY GROUPS AT THE 24-POSITION OF THE SIDE CHAIN, A METHOD FOR PRODUCING THE SAME AND USE THEREOF IN PRODUCTION OF MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129445-A1 | LIPID NANOPARTICLE FORMULATION | TTPA, SREBF1, SREBF2 | VDR 56/4885ADORA3 4621/4885SLC6A2 3243/4885 |
| US-20030166622-A1 | Vitamin D derivatives with acyloxy groups in the side chains, process for their production, and the use for the production of pharmaceutical agents | CYP24A1, CYP2R1, VDR | VDR 3/4885ADORA3 724/4885SLC6A2 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.